Theravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual Meeting
Theravance Biopharma (NASDAQ: TBPH) presented new analyses of ampreloxetine, their investigational treatment for symptomatic neurogenic orthostatic hypotension (nOH), at the American Academy of Neurology 2025 Annual Meeting. The analyses from Phase 3 trials demonstrated the drug's selective mechanism and safety profile.
Key findings showed that patients on ampreloxetine experienced a 58% mean increase in venous plasma norepinephrine levels after 4 weeks, with MSA patients showing a 79% increase. The drug demonstrated sustained improvement in orthostatic blood pressure, particularly in MSA patients. Importantly, ampreloxetine showed no worsening of supine hypertension, a common side effect of current FDA-approved treatments that typically carry black-box warnings.
The data came from two Phase 3 trials (Study 0169 and 0170) involving patients with nOH in multiple system atrophy, Parkinson's Disease, and pure autonomic failure. These results support an ongoing registrational study (CYPRESS) in patients with nOH and MSA.
Theravance Biopharma (NASDAQ: TBPH) ha presentato nuove analisi su ampreloxetina, il loro trattamento sperimentale per l'ipotensione ortostatica neurogena sintomatica (nOH), durante il Meeting Annuale dell'American Academy of Neurology 2025. Le analisi provenienti dagli studi di Fase 3 hanno dimostrato il meccanismo selettivo e il profilo di sicurezza del farmaco.
I risultati chiave hanno mostrato che i pazienti in trattamento con ampreloxetina hanno sperimentato un aumento medio del 58% dei livelli di norepinefrina plasmatici venosi dopo 4 settimane, con i pazienti affetti da MSA che hanno mostrato un aumento del 79%. Il farmaco ha dimostrato un miglioramento sostenuto nella pressione arteriosa ortostatica, in particolare nei pazienti con MSA. È importante notare che ampreloxetina non ha mostrato un peggioramento dell'ipertensione supina, un comune effetto collaterale dei trattamenti attualmente approvati dalla FDA che di solito presentano avvertenze di tipo black-box.
I dati provengono da due studi di Fase 3 (Studio 0169 e 0170) che coinvolgono pazienti con nOH in atrofia multisistemica, malattia di Parkinson e insufficienza autonomica pura. Questi risultati supportano uno studio registrativo in corso (CYPRESS) in pazienti con nOH e MSA.
Theravance Biopharma (NASDAQ: TBPH) presentó nuevos análisis de ampreloxetina, su tratamiento en investigación para la hipotensión ortostática neurogénica sintomática (nOH), en la Reunión Anual de la Academia Americana de Neurología 2025. Los análisis de los ensayos de Fase 3 demostraron el mecanismo selectivo y el perfil de seguridad del fármaco.
Los hallazgos clave mostraron que los pacientes tratados con ampreloxetina experimentaron un aumento medio del 58% en los niveles de norepinefrina plasmática venosa después de 4 semanas, con pacientes de MSA mostrando un aumento del 79%. El fármaco demostró una mejora sostenida en la presión arterial ortostática, particularmente en pacientes con MSA. Es importante destacar que ampreloxetina no mostró un empeoramiento de la hipertensión en decúbito, un efecto secundario común de los tratamientos aprobados por la FDA que suelen llevar advertencias de tipo black-box.
Los datos provienen de dos ensayos de Fase 3 (Estudio 0169 y 0170) que involucraron a pacientes con nOH en atrofia multisistémica, enfermedad de Parkinson e insuficiencia autonómica pura. Estos resultados respaldan un estudio registral en curso (CYPRESS) en pacientes con nOH y MSA.
Theravance Biopharma (NASDAQ: TBPH)는 2025년 미국신경학회 연례 회의에서 증상성 신경성 기립성 저혈압(nOH)에 대한 연구 치료제인 암프렐록세틴에 대한 새로운 분석 결과를 발표했습니다. 3상 시험 결과는 약물의 선택적 메커니즘과 안전성 프로필을 입증했습니다.
주요 발견은 암프렐록세틴을 복용한 환자들이 4주 후에 정맥 혈장 노르에피네프린 수치가 평균 58% 증가했으며, MSA 환자들은 79% 증가를 보였다는 것입니다. 이 약물은 특히 MSA 환자에서 기립성 혈압의 지속적인 개선을 나타냈습니다. 중요한 점은 암프렐록세틴이 현재 FDA 승인 치료제의 일반적인 부작용인 누운 자세에서의 고혈압을 악화시키지 않았다는 것입니다.
데이터는 MSA, 파킨슨병 및 순수 자율신경 실패 환자들을 포함한 3상 시험(연구 0169 및 0170)에서 나왔습니다. 이러한 결과는 nOH 및 MSA 환자를 대상으로 하는 현재 진행 중인 등록 연구(CYPRESS)를 지원합니다.
Theravance Biopharma (NASDAQ: TBPH) a présenté de nouvelles analyses sur l'ampréloxétine, leur traitement expérimental pour l'hypotension orthostatique neurogène symptomatique (nOH), lors de la Réunion Annuelle de l'Académie Américaine de Neurologie 2025. Les analyses des essais de Phase 3 ont démontré le mécanisme sélectif et le profil de sécurité du médicament.
Les résultats clés ont montré que les patients sous ampréloxétine ont connu une augmentation moyenne de 58 % des niveaux de noradrénaline plasmatique veineuse après 4 semaines, avec des patients MSA montrant une augmentation de 79 %. Le médicament a démontré une amélioration soutenue de la pression artérielle orthostatique, en particulier chez les patients MSA. Il est important de noter que l'ampréloxétine n'a montré aucune aggravation de l'hypertension en décubitus, un effet secondaire courant des traitements actuellement approuvés par la FDA qui comportent généralement des avertissements de type black-box.
Les données proviennent de deux essais de Phase 3 (Étude 0169 et 0170) impliquant des patients atteints de nOH dans l'atrophie multisystémique, la maladie de Parkinson et l'insuffisance autonome pure. Ces résultats soutiennent une étude d'enregistrement en cours (CYPRESS) chez des patients atteints de nOH et de MSA.
Theravance Biopharma (NASDAQ: TBPH) präsentierte neue Analysen von Ampreloxetin, ihrer experimentellen Behandlung für symptomatische neurogene orthostatische Hypotonie (nOH), auf dem Jahresmeeting der American Academy of Neurology 2025. Die Analysen aus Phase-3-Studien zeigten den selektiven Mechanismus und das Sicherheitsprofil des Medikaments.
Wichtige Ergebnisse zeigten, dass Patienten, die Ampreloxetin einnahmen, nach 4 Wochen einen durchschnittlichen Anstieg der venösen Plasma-Norepinephrinspiegel um 58% erfuhren, wobei MSA-Patienten einen Anstieg von 79% zeigten. Das Medikament zeigte eine anhaltende Verbesserung des orthostatischen Blutdrucks, insbesondere bei MSA-Patienten. Wichtig ist, dass Ampreloxetin keine Verschlechterung der supinen Hypertonie aufwies, einem häufigen Nebenwirkung der derzeit von der FDA zugelassenen Behandlungen, die normalerweise Warnhinweise im Sinne einer Black-Box enthalten.
Die Daten stammen aus zwei Phase-3-Studien (Studie 0169 und 0170), die Patienten mit nOH bei multipler Systematrophie, Parkinson-Krankheit und reiner autonomer Insuffizienz einbezogen. Diese Ergebnisse unterstützen eine laufende Registrierungsstudie (CYPRESS) bei Patienten mit nOH und MSA.
- Drug showed no worsening of supine hypertension, a significant advantage over current FDA-approved treatments
- Strong efficacy with 58% increase in plasma norepinephrine levels, 79% in MSA patients
- Demonstrated sustained improvement in orthostatic blood pressure
- Advancing to registrational study based on positive Phase 3 results
- None.
Insights
The new analyses of ampreloxetine presented at AAN 2025 reveal promising pharmacodynamic and safety characteristics that differentiate this candidate from existing nOH treatments. The data demonstrated 58% mean increase in venous plasma norepinephrine across all patients, with an even more robust 79% increase in MSA patients specifically - indicating strong target engagement where it's most needed. This selective norepinephrine reuptake inhibition translated to sustained improvements in orthostatic blood pressure, particularly in the MSA subgroup.
What's particularly significant is ampreloxetine's safety profile regarding supine hypertension - a serious concern with all current FDA-approved treatments for nOH, which carry black box warnings. Ambulatory blood pressure monitoring, considered the gold standard for detection, showed no worsening of overnight supine hypertension compared to placebo. This could represent a meaningful clinical advantage if confirmed in the ongoing registrational CYPRESS trial.
For a condition with effective long-term treatment options, these mechanistic insights substantiate ampreloxetine's potential to address the persistent unmet need in nOH, especially for MSA patients who often fail multiple antihypotensive agents. While these are secondary analyses rather than primary endpoints from a pivotal trial, they provide important supportive evidence for the ongoing registrational study and suggest ampreloxetine may offer a differentiated clinical profile.
Analyses from Randomized Controlled Trials Further Support the Target Engagement and Safety Profile of Ampreloxetine in Neurodegenerative Disease
The previous Phase 3 program of ampreloxetine, a selective norepinephrine reuptake inhibitor included two back-to-back Phase 3 trials in patients with symptomatic nOH in multiple system atrophy (MSA), Parkinson's Disease and pure autonomic failure (Study 0169, NCT03750552 and Study 0170, NCT03829657). Results from these studies were supportive of a registrational study in patients with nOH and MSA that is currently ongoing (CYPRESS, NCT05696717). Analyses presented at AAN describe ampreloxetine's pharmacodynamic effects over time, demonstrating durable target engagement and a physiological effect on blood pressure.
"There is a persistent unmet need for effective long-term treatments for nOH in patients with MSA. Inadequately treated nOH is associated with rapid functional decline, and many patients fail to respond despite trials of two to three different antihypotensive agents. Currently, there are no approved therapies that improve symptoms long-term, and all carry potential risk of supine hypertension. These new analyses provide evidence of ampreloxetine's highly selective mechanism of action and precise targeting of peripheral nerve activity to relieve symptoms of nOH," said Dr. Valeria Iodice, Honorary Associate Professor in Neurology, National Hospital for Neurology and Neurosurgery, UCL,
Targeted Mechanism of Action in Patients with nOH
Study 0169 enrolled patients with symptomatic nOH, as defined by a 4-point or greater score on a patient reported assessment (OHSA2 scale). Pharmacokinetic and pharmacodynamic measures were taken at baseline and at the end of the 4-week randomized controlled trial period. This was followed by Study 0170 which involved a 16-week open-label period followed by a 6-week randomized withdrawal period.
Key findings include:
- In Study 0169, patients randomized to ampreloxetine experienced a mean increase of
58% in venous plasma norepinephrine levels after 4 weeks of treatment across all patients, which was most pronounced in patients with MSA (79% increase). - The observed shift in the pharmacodynamic profiles demonstrated target inhibition and reduced pre-synaptic uptake of norepinephrine.
- At the end of Week 6 of the randomized withdrawal period in Study 0170, norepinephrine reuptake inhibition with ampreloxetine resulted in a sustained improvement in orthostatic blood pressure, most notably in patients with MSA, which is consistent with enhanced activity of the peripheral autonomic nerves; this was lost in patients that withdrew to placebo.
No worsening of comorbid supine hypertension
In addition to nOH, patients with autonomic failure often have supine hypertension, or high blood pressure when lying down. Currently, all pressor agents approved by the FDA to treat orthostatic hypotension have black-box warnings indicating that these drugs may exacerbate or increase the risk of supine hypertension. Patients enrolled in Study 0169 underwent remote ambulatory blood pressure monitoring at baseline, Day 14 and Day 21, as well as in-clinic blood pressure measurements at baseline and Days 7, 14, 21 and 28.
Key findings include:
- Patients randomized to ampreloxetine did not show worsening of supine hypertension as measured during in-clinic visits.
- Patients randomized to ampreloxetine who completed the ambulatory blood pressure monitoring test at home had no worsening of overnight supine hypertension compared to those on placebo.
- There was no difference in maximal blood pressure excursion detected during the 24-hour monitoring period in patients assigned to placebo or ampreloxetine.
"nOH is a difficult condition to treat, as available pressor agents also raise blood pressure while patients are lying down, which we know increases the risk of hypertensive organ damage to the heart, brain, and kidney," said Dr. Lucy Norcliffe-Kaufmann, Theravance Biopharma's Executive Director of Clinical Science. "This new analysis of ambulatory blood pressure data, which is the 'gold-standard' method for detection, is very promising. Ampreloxetine's unique mechanism of action suggests that it may be an effective therapy for relieving symptomatic nOH without the side effect of high blood pressure in the supine position."
Presentation information:
NET-Inhibition with Ampreloxetine, Blood Pressure, and Catecholamines in Patients with Neurogenic Orthostatic Hypotension
Presenter: Valeria Iodice, MD
Monday, April 7, 11:15 AM PDT (2:15 PM EDT)
The Impact of Ampreloxetine on Supine Hypertension: An Ambulatory Blood Pressure Monitoring Study
Presenter: Lucy Norcliffe-Kaufmann, PhD
Monday, April 7, 11:27 AM PDT (2:27 PM EDT)
Slides presented by Drs. Iodice and Norcliffe-Kaufmann may be found here in the Presentations section of Theravance Biopharma's website.
About Ampreloxetine
Ampreloxetine, an investigational, once-daily norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The unique benefits of ampreloxetine treatment reported in MSA patients from Study 0170 included an increase in norepinephrine levels, a favorable impact on blood pressure, clinically meaningful and durable symptom improvement, and no signal for worsening of supine hypertension. In the US, the Company has been granted an Orphan Drug Designation for ampreloxetine for the treatment of symptomatic nOH in patients with MSA and, if results from the ongoing Phase 3 CYPRESS study are supportive, plans to file an NDA for full approval in this indication.
About CYPRESS (Study 0197), a Phase 3 Study
Study 0197 (NCT05696717) is currently enrolling. This is a registrational Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment; the primary endpoint of the study is change in the Orthostatic Hypotension Symptom Assessment (OHSA) composite score. The Study includes four periods: screening, open label (12-week period, participants will receive a single daily 10 mg dose of ampreloxetine), randomized withdrawal (eight-week period, double-blind, placebo-controlled, participants will receive a single daily 10 mg dose of placebo or ampreloxetine), and a long-term treatment extension. Secondary outcome measures include change from baseline in Orthostatic Hypotension Daily Activity Scale (OHDAS) item 1 (activities that require standing for a short time) and item 3 (activities that require walking for a short time).
About the ampreloxetine Phase 3 Program (Study 169 and Study 170)
Study 0169 (NCT03750552) was a Phase 3, 4-week, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of ampreloxetine compared to placebo in patients with symptomatic nOH (n=195). Patients from Study 0169 were eligible to enter into Study 0170 (NCT03829657), a Phase 3, multi-center, 22-week study comprising a 16-week open-label period and a 6-week double-blind, placebo-controlled, randomized withdrawal period to evaluate the sustained benefit in efficacy and safety of ampreloxetine in patients with symptomatic nOH. The primary endpoint for Study 0170 of treatment failure at week 6 was defined as a worsening of both Orthostatic Hypotension Symptom Assessment Scale (OHSA) question #1 and Patient Global Impression of Severity (PGI-S) scores by 1.0 point. After Study 0169 did not meet its primary endpoint, the Company took actions to close out the ongoing clinical program including Study 0170. The study was more than
About Multiple System Atrophy (MSA) and Symptomatic Neurogenic Orthostatic Hypotension (nOH)
MSA is a progressive brain disorder that affects movement and balance and disrupts the function of the autonomic nervous system. The autonomic nervous system controls body functions that are mostly involuntary. One of the most frequent autonomic symptoms associated with MSA is a sudden drop in blood pressure upon standing (nOH).3 There are approximately 50,000 MSA patients in the US4 and 70
Neurogenic orthostatic hypotension (nOH) is a rare disorder defined as a fall in systolic blood pressure of ⩾20 mm Hg or diastolic blood pressure of ⩾10 mm Hg, within 3 minutes of standing. Severely affected patients are unable to stand for more than a few seconds because of their decrease in blood pressure, leading to cerebral hypoperfusion and syncope. A debilitating condition, nOH results in a range of symptoms including dizziness, lightheadedness, fainting, fatigue, blurry vision, weakness, trouble concentrating, and head and neck pain.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.
Forward-Looking Statements
This press release will contain certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations, and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to: the Company's goals, designs, strategies, plans and objectives, the Company's regulatory strategies and timing of clinical studies (including the data therefrom), the Company's goals, designs, strategies, plans, potential, and objectives, the Company's regulatory strategies and timing of clinical studies, potential or possible safety, efficacy or differentiation of our investigational therapy, and expectations around the use of OHSA scores as endpoints for clinical trials. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: delays or difficulties in commencing, enrolling or completing clinical studies, the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated, risks of decisions from regulatory authorities that are unfavorable to the Company, dependence on third parties to conduct clinical studies, delays or failure to achieve and maintain regulatory approvals for product candidates, risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products, ability to retain key personnel, the ability of the Company to protect and to enforce its intellectual property rights, volatility and fluctuations in the trading price and volume of the Company's shares, and general economic and market conditions. Other risks affecting the Company are in the Company's Form 10-K filed with the SEC on March 7, 2025, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
Contact:
investor.relations@theravance.com
650-808-4045
1 Disclosure: Dr. Iodice is a paid consultant of Theravance Biopharma US, LLC.
2 Orthostatic Hypotension Symptom Assessment, a validated scale assessing the presence of a range of hypotension-related symptoms including dizziness, weakness, problems with vision, fatigue, trouble concentrating, and head/neck discomfort. It is based on a scale from 0 (no symptoms) to 10 (worst possible severity of a symptom).
3 https://medlineplus.gov/genetics/condition/multiple-system-atrophy/
4 UCSD Neurological Institute (25K-75K, with ~10K new cases per year); NIH National Institute of Neurological Disorders and Stroke (15K-50K).
5 Delveinsight MSA Market Forecast (2023); Symptoms associated with orthostatic hypotension in pure autonomic failure and multiple systems atrophy, CJ Mathias (1999).
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-presents-two-new-ampreloxetine-analyses-in-oral-session-at-the-american-academy-of-neurology-2025-annual-meeting-302422404.html
SOURCE Theravance Biopharma, Inc.
FAQ
What were the key efficacy results of ampreloxetine in TBPH's Phase 3 trials?
How does TBPH's ampreloxetine differ from current nOH treatments regarding safety?
What patient populations were included in TBPH's ampreloxetine Phase 3 trials?
What is the current status of TBPH's ampreloxetine development program?
